Speakers 2023

• 

  Adrian Griffin

  Vice-president, HTA and access policy, Johnson & Johnson

  X

  

  Adrian Griffin

  Vice-president, HTA and access policy, Johnson & Johnson

  Adrian Griffin has worked in the life-sciences industry for more than 25 years, predominantly in the fields of health economics, outcomes research and reimbursement policy, with experience across the pharmaceutical, medical-device and diagnostic sectors. As vice-president, health-technology assessment (HTA) and access policy at Johnson & Johnson, Mr Griffin is engaged in numerous multi-stakeholder forums and initiatives that bring regulators and HTA agencies together with companies, improving the transparency and appreciation of different stakeholder perspectives. He served on the NICE Technology Appraisal Committee from 2003 to 2020, and on the board of directors of the International Society for Pharmacoeconomics and Outcomes Research in 2013-15.

• 

  Agata Jakoncic

  Managing director, MSD Greece, Cyprus & Malta

  X

  

  Agata Jakoncic

  Managing director, MSD Greece, Cyprus & Malta

  Agata Jakoncic is managing director of MSD for Greece, Cyprus and Malta. During her career she has held roles in commercial, marketing and supply optimisation. Ms Jakoncic has guided MSD to embrace a new organisational culture, apply agile ways of working, leverage new technologies and launch customer experiences to meet the needs of the external environment. A strong advocate of diversity and inclusion, Ms Jakoncic mentors women in leadership positions and supports the implementation of environmental, social and governance activities at MSD. Ms Jakoncic has served as president of the Pharma Innovation Forum in Greece and is currently a member of its board.

• 

  Alan Lovell

  Senior manager, health policy & insights, Economist Impact

  X

  

  Alan Lovell

  Senior manager, health policy & insights, Economist Impact

  Dr Alan Lovell is a senior associate in the Health Policy and Clinical Evidence Practice. Alan has a degree in Biology from Royal Holloway, University of London, and gained his doctorate from the University of Warwick. He worked as a Postdoctoral Research Fellow at Sainte-Justine Hospital, University of Montreal before receiving an MA with distinction in Information Studies from the University of Brighton. Alan has advised and worked on a range of projects for governments, health ministries, academic journals, healthcare providers, insurers, research funders and sporting associations.

• 

  Anjali Sibley

  Medical director, Stanford Emeryville Cancer Centre

  X

  

  Anjali Sibley

  Medical director, Stanford Emeryville Cancer Centre

  Anjali Sibley is a haematologist and medical oncologist, and medical director of the Stanford Medicine Cancer Centre in Emeryville, California. She manages an innovative cancer survivorship clinic, serves on the Patient Family Advisory Council, and is physician champion for a programme to improve clinical trial enrolment for underserved populations at Stanford. Dr Sibley’s clinical interests include treating solid-tumour cancers, lung cancers, blood cancers and benign blood conditions. She is interested in cancer prevention and reducing disparities in haematologic/oncologic care among underserved populations, and successful cancer survivorship programmes.

• 

  Dr David Baldwin

  Consultant respiratory physician and honorary professor of medicine, Nottingham University Hospitals and the University of Nottingham

  X

  

  Dr David Baldwin

  Consultant respiratory physician and honorary professor of medicine, Nottingham University Hospitals and the University of Nottingham

  David Baldwin is a consultant respiratory physician sub-specialising in lung cancer, mesothelioma and interventional procedures. He is chair of the UK Clinical Expert Group for Lung Cancer, and honorary professor in the School of Medicine at the University of Nottingham. Dr Baldwin’s primary research interests are in CT screening and lung cancer epidemiology. He was lead respiratory physician on the UK CT lung cancer screening trial. Dr Baldwin works with the UK Health Security Agency and is advisor to the UK National Screening Committee. He has been clinical lead on the NICE Lung Cancer Guideline Development Group and chair of the NICE Quality Standards Group on Lung Cancer.

• 

  Dr Yolande Lievens

  Chair radiation oncology department, Ghent University Hospital and associate professor radiation oncology, Ghent University

  X

  

  Dr Yolande Lievens

  Chair radiation oncology department, Ghent University Hospital and associate professor radiation oncology, Ghent University

  Yolande Lievens is chair of the radiation oncology department at Ghent University Hospital and associate professor at Ghent University. While her clinical focus is on radiotherapy for thoracic malignancies, she has a specific interest in the quality and organisation of radiotherapy, the position of radiotherapy in multidisciplinary oncology, and health-economic aspects of cancer care. Dr Lievens is former president of the European Society for Radiotherapy and Oncology and of the Belgian College for Physicians in Radiation Oncology. She co-chairs the ESTRO-HERO project and is principal investigator of the EORTC/ESTRO E2-RADIATE initiative.